The European Commission has approved the first Important Project of Common European Interest (IPCEI), under EU State aid rules, to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals. The project, named ‘IPCEI Med4Cure', was jointly notified by six Member States: Belgium, France, Hungary, Italy, Slovakia and Spain. This follows the March 2022 joint Manifesto towards a heath IPCEI, signed by 16 Member States. Member States will provide up to €1bn in public funding, which is expected to unlock additional €5.9bn in private investments, and this funding is for the first IPCEI projects. It focuses on innovation in production technologies of medicines, tackling antimicrobial resistance, rare diseases and emerging health threats and development of cell and gene therapies. Overall the IPCEI involves 14 projects from 13 companies, which is intended to foster 70 collaborations, and around 6000 with an overall completion plan for 2036. In addition to the IPCEI Med4Cure, the Commission also approved the IPCEI Hy2Move, on the basis of the 2021 IPCEI Communication, where several Member States can support transnational projects of strategic significance for the EU under Article 107(3)(b) of the Treaty on the Functioning of the European Union.